Adamed

Executive Summary

Adamed is a Polish pharmaceutical and biotechnology company founded in 1986, built on a foundation of Polish scientific research and a substantial patent portfolio. The company develops, manufactures, and commercializes a broad portfolio of prescription drugs, OTC products, dietary supplements, dermocosmetics, and medical devices, with a focus on addressing chronic civilization diseases. Adamed has expanded its global footprint through international offices and strategic acquisitions, positioning itself as a key player in the Central and Eastern European pharmaceutical market. The company's growth strategy centers on organic pipeline development and targeted acquisitions to broaden its therapeutic reach. With a strong emphasis on R&D, Adamed continues to advance its biologics and small molecule programs, targeting unmet medical needs in oncology, cardiology, and neurology. Recent initiatives include expansion into Western European and Asian markets, leveraging its manufacturing capabilities and regulatory expertise. As a private entity, Adamed maintains financial flexibility and reinvests profits into innovation, making it well-positioned for sustained long-term growth.

Upcoming Catalysts (preview)

• Q3 2026Potential approval of new oncology drug candidate in EU55% success
• Q2 2026Announcement of strategic partnership for biosimilar development70% success
• Q4 2026Acquisition of a complementary late-stage asset in cardiovascular disease60% success